The GLP-1 RA semaglutide was associated with a 40%-70% reduced risk for first-time diagnosis of AD in patients with type 2 diabetes, real-world data show.
had a significantly lower risk for AD compared with their peers who were prescribed any of seven other antidiabetic medications, including other types of GLP-1 receptor–targeting medications.
In a real-world analysis, Xu and colleagues used electronic health record data to identify 17,104 new users of semaglutide and 1,077,657 new users of seven other antidiabetic medications, including other GLP-1 RAs, Compared with the other medications, semaglutide was associated with a 40%-70% reduced risk for first-time diagnosis of AD in patients with type 2 diabetes, with similar reductions seen across obesity status and gender and age groups, the authors reported.
Alzheimer Disease Diabetes Mellitus Type 2 Diabetes Mellitus Type Ii Type 2 Diabetes Type 2 DM T2DM T2D Brain Clinical Research Clinical Trials Clinical Studies Pre-Clinical Trial Double-Blind Study Double-Blind Studies Single-Blind Study Single-Blind Studies Healthcare And Medical Technology Health And Medical Tech Health And Med Tech
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Topline: Oral Semaglutide Cuts Cardiovascular Events in T2DIn Novo Nordisk’s randomized clinical trial, semaglutide reduced the risk for major adverse cardiovascular events by 14% compared with placebo.
Read more »
Oral Semaglutide May Boost Liver Health in Type 2 DiabetesOral semaglutide improved liver health, diabetes status, and lipid profile in patients with MASLD and T2D, with weight loss likely playing a role, showed a prospective study.
Read more »
Semaglutide a Potential Treatment Option for Opioid Use Disorder?Semaglutide was linked to a significantly lower risk of overdose than other antidiabetic drugs in patients with type 2 diabetes and opioid use disorder.
Read more »
Semaglutide may reduce opioid overdoses, a new study suggests A study of people with type 2 diabetes and opioid use disorder suggests that the key ingredient in Ozempic and Wegovy shows promise against addiction.
Read more »
Semaglutide saps mice’s motivation to runMice given semaglutide, the key ingredient in drugs like Ozempic and Wegovy, lost weight, but they also voluntarily ran less on a wheel.
Read more »
Hidradenitis Suppurativa Symptoms Eased by Semaglutide-Aided Weight LossImprovements in the Dermatology Life Quality Index score and hidradenitis suppurativa flares were seen in people who achieved semaglutide-induced weight loss.
Read more »